Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
YEP, gap & trapper, ALL DAY CHOP & GRIND SELL OFF
Wooooooh Dodged a turd here took a loss but damn would been huge loss if didn’t sell pre market. WOW!
Cut my losses pre market chased this one. Good luck all
This will run all day.
After hours trading should be fun.
You can expect $5 here.
ABVC BioPharma Entered Into a Term Sheet to License Global Rights of CNS Drugs with the Indications of MDD and ADHD to AiBtl BioPharma at the Valuation of $667 Million
FREMONT, CA, Oct. 26, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and oncology/hematology, announced today that it entered into a legal binding term sheet regarding a multi-year, global licensing agreement with AiBtl BioPharma (AiBtl) for the Company's CNS drugs with the indications of MDD (Major Depressive Disorder) and ADHD (Attention Deficit Hyperactivity Disorder) (the "Licensed Products"). The potential license will cover the Licensed Products' clinical trial, registration, manufacturing, supply, and distribution rights.
The Licensed Products for MDD and ADHD, owned by ABVC and its subsidiary BioLite, Inc., were valued at $667M by a third-party evaluation. ABVC and AiBtl are determined to collaborate on the global development of the Licensed Products. They are also working to strengthen their new drug development and business collaboration, including technology, interoperability, and standards development. In this legally binding term sheet, ABVC's licensing revenues for ABVC and its subsidiary BioLite, Inc. include the AiBtl stock of 46 million shares (57% of AiBtl) and milestone cash payments of $7M with the royalties of 5% of net sales, up to $200 million, after the product's launch.
AiBtl is a US company registered in Delaware that owns 51% of Jeremy Group Co, LTD. (JEREMY), an Asian company with assets valued at $32M. JEREMY develops and constructs 607,000 square meters of land in the Asia Economic Development Zone. One of the objectives of AiBtl’s collaboration is to integrate the health and resort industries. Additionally, the venture will capitalize on development revenues within the Asia Economic Development Zone, primarily through land lease income. "AiBtl aims at going IPO and getting listed on NASDAQ in 2024," said AiBtl Chief Executive Officer Russman Jaimes.
"AiBtl has a strong capability in its global business development. We believe partnering with AiBtl will allow us to secure international pharmaceutical companies to develop the Licensed Products and bring the CNS drugs to the market," said Dr. Uttam Patil, ABVC Chief Executive Officer. "This will allow ABVC to continue to focus on bringing its other proprietary patented products, such as ophthalmology medical devices, Vitargus, and oncology drugs, to the global market."
We believe the Company's pipeline products have great market potential. As per the Future Market Insights report, the MDD market was valued at $11.51 billion in 2022 and is expected to reach $14.96 billion by 2032 with a CAGR of 2.8% over the forecast period[1]. According to the Polaris market research report, the global ADHD treatment market was valued at $15.23 billion in 2022 and is expected to grow at a CAGR of 7.3% over the forecast period between 2023-2032.[2]
ABVC BioPharma Entered Into a Term Sheet to License Global Rights of CNS Drugs with the Indications of MDD and ADHD to AiBtl BioPharma at the Valuation of $667 Million
Very very thin
New 52= week low yesterday rallied today
ABVC Signs a Term Sheet to Earn Licensing Fees of up to $20M and Royalties of 5-12% of Net Sales
$ABVC - 👆Up 58% Pre-Market/ Current Price $3.94
Signs a Term Sheet to Earn Licensing Fees of up to $20M and Royalties of 5-12% of Net Sales
HI MONK!! HOPE DOING GREAT.
WHAT IS YOUR TAKE AS PER THE ABVC MARKET REACTION******
**** announced today that it has signed a term sheet to advance a partnership with Zhonghui United Technology (Zhonghui) Group Co., Ltd. and its affiliated enterprises. The partnership contemplates a planned acquisition of real estate assets via an equity transfer, estimated at $7.4 million, all to advance the development of a large-scale health and wellness base in Chengdu, China.
ABVC trading post reverse split now No 2 on the Barchart Top 10
https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc
$ABVC - Signs Term Sheet to Acquire Real Estate Assets for Strategic Investments
ABVC to transfer shares to Zhonghui at $20 per share for a 20% ownership of Zhonghui's property near Chengdu, China, estimated at $37m
Up 46% Pre-Market/ Current Price $5.58
Looking good so far ! Still going long
$ABVC: Shes going now...... $0.95
Lets see how high she rolls.
GO $ABVC
SEC Charges Eight Social Media Influencers in $100 Million Stock Manipulation Scheme Promoted On Discord and Twitter. ABVC was a target.
https://www.sec.gov/litigation/litreleases/2022/lr25591.htm
Complaint: ABVC on pages 16,17
https://www.sec.gov/litigation/complaints/2022/comp-pr2022-221.pdf
$ABVC long @1.05
great r/r, no shares available to short, insider bought 7 Million shares few days ago, great chart and former supernova, bottomed chart. Zacks has PT $9.50 six days ago!
Could run anytime and big, ww!
$5.00 plus this week
#ABVC
$7.00 plus thus week
#ABVC
Another pos that was pump and dumped?? Imo
Hope so hanging on $$$
I have a feeling big bounce back up to $7.00
Coming soon imo.
#ABVC
ABVC almost total retracement
SMH
sick
so sick
thats why if bbby pops again, Im going short aGAIN
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=166607765
That’s the plan
Closing green today
#ABVC
Followers
|
12
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
277
|
Created
|
02/28/08
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |